Patents by Inventor NANDINI ACHARYA

NANDINI ACHARYA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957695
    Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 16, 2024
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Patent number: 11793787
    Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: October 24, 2023
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20210100774
    Abstract: The subject matter disclosed herein is generally directed to modulating anti-tumor T cell immunity by modulating steroidogenesis. Steroidogenesis may be modulated with inhibitors of enzymes that synthesize glucocorticoids in a tumor. The inhibitor may target Cyp11a1. The inhibitor may be metyrapone. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 8, 2021
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20190365781
    Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.
    Type: Application
    Filed: April 26, 2019
    Publication date: December 5, 2019
    Inventors: Ana Carrizosa Anderson, Asaf Madi, Nandini Acharya, Vijay K. Kuchroo, Aviv Regev
  • Publication number: 20170112787
    Abstract: Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include Anandamide. The methods are particularly useful to treat gut inflammation associated with diabetes mellitus Type I.
    Type: Application
    Filed: May 5, 2016
    Publication date: April 27, 2017
    Inventors: PRAMOD SRIVASTAVA, NANDINI ACHARYA, SREYASHI BASU